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Identifying mutations in Tunisian 
families with retinal dystrophy
Imen Habibi1,2,3,4, Ahmed Chebil2,5, Yosra Falfoul2,5, Nathalie Allaman-Pillet1, Fedra Kort2,5, 
Daniel F. Schorderet1,4,6 & Leila El Matri2,5
Retinal dystrophies (RD) are a rare genetic disorder with high genetic heterogeneity. This study 
aimed at identifying disease-causing variants in fifteen consanguineous Tunisian families. Full 
ophthalmic examination was performed. Index patients were subjected to IROme analysis or whole 
exome sequencing followed by homozygosity mapping. All detected variations were confirmed by 
direct Sanger sequencing. Mutation analysis in our patients revealed two compound heterozygous 
mutations p.(R91W);(V172D) in RPE65, and five novel homozygous mutations: p.R765C in CNGB1, 
p.H337R in PDE6B, splice site variant c.1129-2A > G and c.678_681delGAAG in FAM161A and 
c.1133 + 3_1133 + 6delAAGT in CERKL. The latter mutation impacts pre-mRNA splicing of CERKL. The 
other changes detected were six previously reported mutations in CNGB3 (p.R203*), ABCA4 (p.W782*), 
NR2E3 (p.R311Q), RPE65 (p.H182Y), PROM1 (c.1354dupT) and EYS (c.5928-2A > G). Segregation 
analysis in each family showed that all affected individuals were homozygotes and unaffected 
individuals were either heterozygote carriers or homozygous wild type allele. These results confirm the 
involvement of a large number of genes in RD in the Tunisian population.
Retinal dystrophies (RD) are a heterogeneous group of diseases in which the photoreceptor and RPE cells of the ret-
ina degenerate, leading to partial or complete blindness and affecting approximately 1 in 2500–3500 individuals1. 
Classification of RD is generally based on whether the disease primarily affects cones or rods (predominantly 
affecting the macula or peripheral retina respectively) and whether it occurs alone (non-syndromic RD) or in 
conjunction with other systemic disorders, especially loss of hearing (syndromic RD).
RD phenotypes are variable in terms of onset, progression and severity. The disease may be mild and non pro-
gressive, such as in congenital stationary night blindness (CSNB), characterized by defective rod photoreceptors 
involved in night vision. Non progressive disorders may lead to severe visual impairment as well as achromatop-
sia (ACHM), stationary congenital cone dystrophies. Other disorders are progressive, leading to severe visual 
impairment such as in retinitis pigmentosa (RP), cone dystrophy (CD), cone-rod dystrophy (CRD)2 and Stargardt 
disease (STGD)3. In RP, rod photoreceptors are initially affected more severely than cones4. The most severe 
cases are Leber Congenital Amaurosis (LCA) and early-onset rod–cone dystrophies, in which infants suffer from 
complete blindness from birth or within the first years of life5. Cone dystrophies are characterized by progressive 
degeneration of cone photoreceptors with preservation of rod function6, whereas in CRD peripheral vision is also 
compromised, leading to early blindness. Stargardt disease is a juvenile macular degeneration characterized by 
central vision loss3.
This group of rare genetic disorders shows substantial clinical and genetic overlaps with high genetic heter-
ogeneity involving more than 220 genes identified so far (https://sph.uth.edu/retnet/). Similar phenotypes may 
result from different gene mutations, and subtle differences in phenotypes may result from a similar mutation7.
The mutations in causative genes induce either in degeneration or dysfunction of retinal cells. Functionally, 
different gene products are involved in many cellular functions and fall into four categories: proteins directly 
involved in the phototransduction cascade, genes encoding proteins responsible for the structure and polarity of 
the photoreceptors, genes encoding proteins of the visual cycle, and regulatory genes (such as transcription and 
splicing factors)2.
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All modes of mendelian inheritance have been described in RD, with autosomal recessive being the most 
prevalent2. In our study we focused on the Tunisian population, known to have a relatively high level of con-
sanguineous marriages, leading to a relatively high frequency of autosomal recessive diseases. This study was 
designed to apply homozygosity mapping in 15 consanguineous Tunisian families segregating retinal degenera-
tive disease and three families analyzed by IROme7, aiming at the identification of the genetic defects.
Materials and Methods
Subjects. The department B of Hedi Rais Institute of Ophthalmology in Tunisia recruited all subjects involved 
in the study over a 10-year period. 177 Tunisian families segregating RD were enrolled. In this pilot study, a subset 
of 61 individuals (32 affected, 29 unaffected) from 15 families with clear recessive transmission and two or more 
affected individuals was selected. The affected individuals comprised 17 males and 15 females, ranging in age 
from 4 to 72 years, with an onset of disease ranging from birth to 47 years. Demographic characteristics, age at 
onset, and personal and family history were recorded for all participants. Written informed consent was obtained 
from each study participant, analyses were done in accordance with local guidelines and regulations study was 
approved by the Local Ethics Committee of the Hedi Rais Institute.
All patients underwent a standard ophthalmological examination including determination of best corrected 
visual acuity using standard Snellen charts. Clinical examination was supplemented by fundus photography, color 
vision assessment using the Farnsworth-Munsell 100 hue color vision test (FM100, Munsell Color Company 
Inc., Baltimore, MD, USA) and analysis of dark adaptation. Goldmann kinetic perimetry (Carl Zeiss Meditec 
Inc., Dublin, CA, USA) using V-4e and I-4e targets, fluorescein angiography (Imagenet; Topcon Corporation, 
Tokyo, Japan) and optical coherence tomography (SD-OCT) (OCT 3D TOPCON 2000) was also performed. 
Electrophysiological investigation was carried out using the Mé trovision vision monitor (Mé trovision, Pé renchies, 
France) according to the International Society for Clinical Electrophysiology of Vision (ISCEV) protocol.
Homozygosity mapping and mutation analysis. Genomic DNA of participating individuals was iso-
lated from peripheral blood using a standard salting out procedure. One index patient of 12 families was selected 
for whole exome sequencing (WES) analysis and unaffected family members were collected for co-segregation 
analysis. Three index patients were analyzed with IROme8.
Exome capturing was performed with the Roche Nimble-Gen version 2 (44.1–megabase pair) at Otogenetics 
Corporation (Norcross, Georgia) and sequencing was done on an Illumina HiSeq2000 at a mean coverage× 31. 
Sequence reads were aligned to the human genome reference sequence (build hg19), and variants were identi-
fied and annotated using the Nextgene software package v.2.3.5. (Softgenetics, State College, PA). Homozygosity 
was evaluated from SNPs obtained by WES. In families with CERKL mutations, SNPs: rs4667591, rs1050354, 
rs4894140, rs1143676, rs3754929, rs1400130, rs12476147, rs17228441, rs1800255, rs1225090 were selected and 
analyzed by Sanger sequencing in the index patients of families F12-F15.
Assessment of the Pathogenicity of Candidate Variants. We applied various bioinformatic tools 
to filter variants against NCBI dbSNP to facilitate the identification of disease-causing mutations. The Exome 
Aggregation Consortium (ExAC; http://exac.broadinstitute.org) data set was used as a reference data set of 
population-based allele frequencies9. Novel DNA variations were compared with data from public databases 
(HGMD10 and 1000 genomes11). Although most causative mutations associated with RD are rare (MAF < 0.01). 
The putative pathogenicity of the novel missense variants reported in this study was evaluated using two in sil-
ico tools: Polymorphism Phenotyping v2 (PolyPhen-2)12 and Sorting Intolerant from Tolerant (SIFT)13. The 
PolyPhen-2 score ranges from 0.0 (tolerated) to 1.0 (deleterious). Variants with scores of 0.0 are predicted to be 
benign. Values of 1.0 or close to 1.0 are more confidently predicted to be deleterious. PolyPhen-2 and SIFT scores 
use the same range, 0.0 to 1.0, but with opposite meanings. A variant with a SIFT score of 1.0 is predicted to be 
benign. In addition, we determined with PolyPhen-2 a measure of evolutionary nucleotide conservation.
Mutation analysis. After all filtering steps, Sanger sequencing was used to verify each predicted 
disease-causing variants remaining in the autozygous regions of interest and to perform cosegregation analy-
ses. PCR was realized in a total reaction mixture of 20 μ l, containing 20 ng of genomic DNA, 10 pmol of each 
primer (Eurogentec, Liège, Belgium) and 10 μ l of FastStart PCR Master Mix (Roche, Basel, Switzerland). Three 
amplification steps (30 s each), with the annealing temperature ranging from 58 °C to 60 °C, were performed. 
Primer sequences were designed using the PRIMER3 software (http://frodo.wi.mit.edu/) and PCR conditions 
are provided in Table 1. The purified PCR products were then directly sequenced on an ABI 3100XL DNA auto-
mated sequencer (Applied Biosystems, Foster city, CA), using the Big Dye Terminator Labeling Kit version 1 (Life 
Technologies, Zug, Switzerland). Cosegregation analysis was performed in all families.
Splicing variant analysis. A minigene analysis was done to predict the putative impact of the deletion 
c.1133 + 3_1133 + 6delAAGT occurring in a splice site. The mutated region was amplified by PCR from DNA 
of patient VI-1, VI-2 in F13 and one healthy control using specific (forward: 5′ -TCC AAA GGA TCC GGG 
AAC TGA AGA GAA AGT GAG G-3′ and reverse: 5′ -TCC AAA GAA TTC GGC TGA GTG AGT AGT TGT 
TTG C-3′ ). The resulting PCR products were subsequently cloned into the pBK-CMV vector using the T4 DNA 
Ligase according to manufacturer’s protocol (Rapid DNA Ligation Kit). Plasmids were analyzed by direct Sanger 
sequencing and then transfected into HEK293 cells. Total RNA was extracted with TRIzol (Invitrogen product 
name), retrotranscribed with the AffinityScript RT (AffinityScript QPCR cDNA Synthesis Kit – Agilent), and the 
resulting cDNA was PCR-amplified using the previously described primers but without the restriction enzyme 
sites (forward: 5′ -GGG AAC TGA AGA GAA AGT GAG G-3′ ) and (reverse: 5′ -GGC TGA GTG AGT AGT TGT 
TTG C-3′ ). The amplified products were separated by electrophoresis on a 2% agarose gel and were subsequently 
analyzed by Sanger sequencing.
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Results
Clinical features. As summarized in Table 2, patient phenotypes included RP and early-onset retinal degen-
eration (EORD) and STGD (Fig. 1). The clinical presentation of patients in families F2, F4, F5, F7, F8, F10 and 
F11 showed typical hallmarks of RP symptoms for which affected individuals initially experienced night blind-
ness with progressive visual loss and hemeralopia in the majority of cases. Specifically, affected individual IV-5 
(aged 40 years) of F2 family reported poor visual acuity. Funduscopy revealed typical RP changes with macular 
atrophy in F10 affected members suffering from photophobia; onset of symptoms was reported to occur during 
the first decade of life, with typical RP changes and normal macula. Fundus examination of patient III-10 (aged 
36 years) of F10 revealed normal macular pattern with typical RP, with no nystagmus or hemeralopia. In F11, the 
index patient V-1 presented typical RP with atrophy of the retina and macular edema.
In addition, clinical data of F9, F12, F13, F14 and F15 (Fig. 2) showed typical hallmarks of RP symptoms for 
which affected individuals initially experienced night blindness with progressive visual loss and hemeralopia in 
the majority of cases. Fundoscopy revealed mild optic disc and retinal atrophy without pigmentation. Macula was 
normal in young patients and showed atrophic alteration in advanced stages.
Intermediate phenotypes between LCA and RP were observed in two families. In F1 and F6 the affected indi-
viduals had poor visual acuity at the ages of 10–12 years respectively, with a clinical picture suggesting EORD. 
Two retinal patterns were identified: pattern 1 presented mid-peripheral deep white dot deposits and virtually no 
clumped pigmentation (F1), whereas pattern 2 showed mid-peripheral pigmented clumps with no white deposits 
(F6). Family F3 presented a very advanced form of STGD. Night blindness was the first symptom, followed by 
intense photophobia. All had useful vision until the second decade of life. Fundus examination revealed atrophy 
of the macula, pallor of the optic disk and bone spicule-shaped pigment deposits in the periphery. SD-OCT show 
diffuse atrophy with Epiretinal membrane. Only family F3 presented a Stargardt phenotype. All cases presented 
non-syndromic phenotype (no associated extraocular abnormalities).
Mutation analysis. Following the clinical diagnosis of retinal dystrophy, WES or IROme was performed 
to screen for all known genes and to look for novel candidate genes. Assuming identity-by-descent in these con-
sanguineous families, we identified and examined autozygous regions when they spanned more than 5 Mb of 
genomic DNA. After all filtering steps, a few strong candidate genes remained in the autozygous regions of inter-
est. Known RD genes were selected first for direct sequencing.
Mutation analysis in our patients revealed seven novel homozygous mutations. The first mutation found 
was a missense substitution, c.2293C > T, in exon 23 of CNGB1 (NM_001297.4), resulting in p.R765C (Fig. 3A) 
detected in family F2. It is considered to be probably damaging with a score of 1.0 by polyphen-2 and R765 is con-
served from mammals to Danio rerio (Zebrafish). The second variant was the substitution of A to G at nucleotide 
position 1010 in exon 7 of the PDE6B (NM_001145291.1) and resulted in the substitution of histidine (H) by argi-
nine (R) at codon 337 (p.H337R) (Fig. 3D) in family F10. This variant is predicted to be benign with polyphen-2 
(Table 3). This amino acid is also conserved from mammals to Danio rerio. These two mutations were amongst 
those included in the evaluation of IROme8.
Genes Exon Forward Reverse 
Hybridation 
temp. (°C)
CNGB3 5 GTGAGAACATGCGGTGTTTG CAAAGATGGGCAAATGATCC 58
CNGB1 23 AGAGACTCCGCCTCTCACTC GGGGCAGACACGAAGATG 58
ABCA4 15 AGCACATGGAGTGTGCGTAG TGCCCCTGTACATTTTAGCC 58
NR2E3 6 TCTGAGCCTCTGGCTGATGTCA AGAAGGGAGTCCAGCCTCAC 60
RPE65 4 GACTTGATGAGGACACATAG CAGTCCAGTAATTTTCAAGC 60
RPE65 6 TTCAAGGGGTAGTGATGACC GCACAAAATGCTATTCTGAC 60
RPE65 11 CTTAGGAGCCAAGACTTAAG GAGGAAACTCAAATGCTACG 60
PROM1 12 ctccagccttagtccagcag gtcccatcacagcaggatct 58
EYS 29 AATCTGCTTCTGGCTTTGTTT GCCCCACTAGCCAGAAAATA 58
PDE6B 7 CCTGCACACAGACATCCAGT TGGCAGAGACAAGGAGAAGC 58
FAM161A 3 TGGTCACATACAACTGAAAGTATAACA GCTTCTGTTCCTCCCTTGCT 60
CERKL 8 GGGAACTGAAGAGAAAGTGAGG GGCTGAGTGAGTAGTTGTTTGC 58
LRP2 69 TTTTTGCTCCCCATCTTCTG AATTCAGCAGGTGGGAGTTG 58
PPIG 14 CATTTCCCCAATTCTTTTTCTT GATTGTGCGCGTCTATCCTT 58
CWC22 10 GCTCCTGGAAAGACCAACAG GCCTCTTTCCAACTAACATGC 58
ITGA4 24 AAAACCAGGTTGCTTTTTGC ACCATGCTTGTTCCTTCCAC 58
PDE1A 7 ACAGGGTGCACTGAAAGTCC TTCTGGGCAGAGACAGATTG 58
NCKAP1 11 AGCAACATAAGAAAGGCAGGA GAAGAATGCAGGGAGGTACG 58
ZNF804A 4 CCACTGTTGCTGAAGATCCA TTTGATCTGCTAATGGGACTGA 58
FSIP2 12 ATCCCTGATTGTGGCAATTC AAGCAGACTGTTCAAGGGCTA 58
COL3A1 30 TAGTTCCCACCCAGCTGTTC CAGCAGCACCCTGAAAATAA 58
ANKAR 16 TGTCAATATAGCATACCCCTTTG TTTTTGGCTTATTTCTCCAAGA 58
Table 1.  Sequences of primers and PCR condition.
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Two new mutations were found in RPE65. The first was in the splice site of RPE65 at position c.1129-2 
and changed the canonical splice site second nucleotide to G in family F6 (Fig. 3B). The second mutation was 
identified in family F7 and was a new compound heterozygous mutations c.[325C > T];[569T > A] resulting 
in p.(R91W);(V172D) (Fig. 3C). The V172D mutation was not described in ExAC Browser9, 1000 genomes11, 
and HGMD10 databases; this mutation is predicted to be possibly damaging with a score of 0.721. In family 
F11 we identified several genomic homozygous regions, one of which included FAM161A. Sequence analysis 
and validation by Sanger sequencing showed a new homozygous deletion of four nucleotides GAAG in exon 3 
(c.678_681delGAAG) (Fig. 3E) resulting in a frameshift and a termination codon at position p.K227Nfs*17. To 
our knowledge, this mutation has not previously been reported in the literature or as variation in databases such 
as 1000 genomes11 and ExAC. The last mutation was a 4-bp deletion, c.1133 + 3_1133 + 6delAAGT, located in 
the donor splice site of intron 8 of CERKL in family F12 (Fig. 3F). This new deletion was present at a homozygous 
state in the two affected sons and was heterozygous in the parents. It was not present in the unaffected sister. 
Furthermore, this deletion affects the invariant acceptor site of exon 8, which has not previously been linked to 
this particular RP phenotype. Minigene analysis confirmed that this variant has a strong impact on the normal 
splicing pattern of CERKL. Transfection of HEK 293 cells with minigene constructs supporting this change and 
its wild-type counterpart revealed that c.1133 + 3_1133 + 6delAAGT did affect the canonical splicing of exon 8 
by knocking down its natural 3′ splice site (Fig. 4).
As the fundus of affected F12 family members showed atrophy of the peripheral retina with no clumped 
pigmentation, we looked for this specific phenotype in families with simplex cases or where consanguinity was 
not evident. Fourteen additional Tunisian families were screened for this specific mutation. This allowed us to 
identify the homozygous c.1133 + 3_1133 + 6delAAGT deletion in three seemingly unrelated families (F13, F14, 
F15), but originating from the same geographical area. Genotype analysis of these three families showed a com-
mon homozygous region of 5.7 cM. This is indicative of an unknown consanguinity of these families (Table 4).
The mutations identified in the other families have already been reported in the literature. These changes 
were two nonsense substitutions: p.R203* in CNGB3 (NM_019098.4) in family F1 and p.W782* in ABCA4 
(NM_000350.2) in family F3; two missense mutations: p.R311Q in NR2E3 (NM_014249.3) in F4 and p.H182Y 
in RPE65 (NM_000329.2) in F5, one frameshift mutation: c.1354dupT in PROM1 (NM_001145848.1) in F8, and 
one splice site mutation: c.5928-2A > G in EYS (NM_001292009.1) in F9. A summary of these results is presented 
in Table 3. Cosegregation analysis in each family showed that all affected individuals were homozygotes and unaf-
fected individuals were either heterozygous carriers or homozygous for the wild type allele (Fig. 5).
Discussion
Molecular diagnosis of RD is a challenging task given the high genetic heterogeneity of this group of diseases. 
Aiming to identify the molecular origin of RD in our Tunisian population, we performed molecular analysis 
of index cases from Tunisian families and revealed a great genetic variety among this population. Ten different 
genes were involved in 15 families. Previous studies in the Tunisian population have shown a high genetic heter-
ogeneity in RP patients14 as well as in patients with Usher syndrome15. This could be explained by the degree of 
consanguinity observed in various parts of the country. The genes identified play different roles in the retina. Most 
genes mutated in this sub-cohort are a part of three major processes in rod photoreceptors and RPE. The first 
Family F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15
Individual VI-1 IV-5 IV-1 IV-1 IV-5 IV-2 V-1 III-3 IV-2 III-9 V-1 VI-1 V-5 III-5 II-5 
Gender Male Female  Female Male Male Male Male  Male Male Male Female  Male  Male  Male  Female  
Age (Years) 12 40 35 28 46 10 14 41 38 36 35 14 28 27 38 
Age of onset 5 6 12 4 Infancy Since birth Since 
birth 
10 22 4 12 4 13 25 Infancy 
Age at last 
follow-up 
11 34 31 26 45 9 12 39 37 34 34 14 28 27 38 
Legally blind - - + - + + + + + - - - - + - 
Photophobia + + + + - + + - + +++ - - + + + 
Nystagmus - - - - - - ++ ++ ++ - - - - - - 
Hemeralopia - ++ - ++ + ++  + + - ++ - ++ + ++ 
Visual acuity 
RE/LE 
7/10 
7/10 
2/10 
2/10 
1/16 
1/16 
5/10 
4/10 
1/50 
1/50 
1/10 
1/10 
<1/10 
<1/10 
1/20 
1/20 
1/10 
1/10 
3/10 
3/10 
2/10 
2,5/10 
4/10 
5/10 
4/10 
2/10 
1/10 
1/10 
2/10 
3/10 
Fundus 
photography 
mid-
peripheral 
deep white 
dot 
deposits 
and virtually 
no clumped 
pigmentatio
n 
Typical RP 
changes 
with bone 
spicule-
shaped 
pigment 
deposits in 
the mid 
periphery 
along with 
atrophy of 
the retina, 
narrowing 
of the 
vessels, 
waxy optic 
discs and 
macular 
atrophy 
Macular 
atrophy 
with 
pigmentatio
ns 
and 
peripheral 
RPE 
atrophy. 
Few bone 
spicule-
shaped 
pigment 
deposits in 
the mid 
periphery 
along with 
atrophy of 
the 
periphery 
retina, 
narrowing 
of the 
vessels  
Typical RP 
changes 
with bone 
spicule-
shaped 
pigment 
deposits in 
the mid 
periphery 
along with 
atrophy of 
the retina, 
narrowig of 
the vessels, 
atrophy of 
the macula 
and slight 
optic discs 
Diffuse 
retinal 
atrophy 
with mid-
peripheral 
pigmented 
clumps 
without any 
white 
deposits 
White 
deposits 
in the mid 
periphery, 
Mild optic 
atrophy, 
Narrowing 
of the 
vessels 
Macular 
atrophy with 
pigmentation
s 
Typical RP 
changes with 
bone spicule-
shaped 
pigment 
deposits in 
the mid 
periphery 
along with 
atrophy of 
the retina, 
narrowing of 
the vessels 
and pallor 
disc 
Diffuse 
retinal 
atrophy 
with 
pigment 
clumping 
and bone 
spicule 
pigmentatio
n, 
attenuated 
blood 
vessels 
with mild 
optic 
atrophy 
Typical RP 
changes 
with few 
bone 
spicule-
shaped 
pigment 
deposits in 
the mid 
periphery 
along with 
atrophy of 
the retina, 
narrowing 
of the 
vessels a 
and slight 
pallor disc
Typical 
RP 
change
s with 
few 
bone 
spicule-
shaped 
pigment 
deposit
s in the 
mid 
peripher
y along 
with 
atrophy 
of the 
retina, 
narrowi
ng of 
the 
vessels 
a and 
slight 
pallor 
disc 
mid-
periph
eral 
retinal 
atroph
y and 
virtuall
y no 
clumpe
d 
pigmen
tation 
mild 
optic 
disc 
atroph
y  
atrophy of 
the 
periphery 
retina and 
virtually 
no 
clumped 
pigmentat
ion 
mild optic 
disc 
atrophy 
atrophy of 
the 
periphery 
retina and 
virtually 
no 
clumped 
pigmentat
ion 
mild optic 
disc 
atrophy 
Diffuse 
retinal 
atrophy 
with few 
pigment 
clumping 
pigmentat
ion in the 
peripheral 
retina, 
attenuate
d blood 
vessels 
with mild 
optic 
atrophy 
optical 
coherence 
tomography 
Normal Macular 
atrophy 
Macular 
atrophy 
Macular 
edema 
Macular 
atrophy 
Macular 
edema 
Macular 
atrophy 
Macular 
atrophy 
Macular 
atrophy 
Normal Macular 
edema 
Normal Normal  Macular 
atrophy  
Macular 
atrophy 
Other 
Disease 
No No No No No No No  No No No High 
myopia 
No  No  No  No  
Table 2.  Clinical features of the patients examined. + and − symbols indicate presence/absence, as well as 
degree of a given feature (+ mild, ++ moderate, +++ severe). F: family; RE: right eye; LE: Left eye.
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three genes, PDE6B, CNGB1 and CNGB3, are implicated in the phototransduction cascade: PDE6B, encoding the 
beta-subunit of rod cGMP-phosphodiesterase (cGMP-PDE), is a key enzyme of the retinal rod phototransduc-
tion cascade. PDE6B was reported by several groups as one of the causative gene associated with arRP, including 
previous studies of consanguineous Tunisian families16–19. Mutations in CNGB1 encoding the beta-subunit of 
the rod cGMP-gated channel explain about 4% of autosomal recessive non-syndromic RP4. We discovered a new 
p.R765C homozygous missense substitution in exon 23 of CNGB1 in F2. This mutation occurred at an evolution-
arily conserved position from mammals to zebrafish and is predicted to damage the protein. So far, only eight 
point mutations were described with convincing evidence. Four of them were non-sense. Our result concurred 
with that of Bariel et al., who found mutation in CNGB1 in a consanguineous French family affected with severe 
autosomal recessive RP (arRP)20. CNGB3 encodes the β -subunit of the cone photoreceptor cGMP-gated chan-
nel, essential for phototransduction in all three classes of cones21. Mutations in this gene are a common cause of 
Figure 1. Clinical features of patients. Fundus photographs of (A) left eye of index patient (F8) with PROM1 
mutation; (B) right eye of IV-4 patient (F3) with ABCA4 mutation; (C) left eye of index patient (F5) with RPE65 
mutation; (D) right eye of the index case (F2) with CNGB1 mutation; (E,F) left eye of subject IV-1 in family F4 
with NR2E3 mutation; (G) right eye of subject VI-1 (F1) with CNGB3 mutation; (H) right eye of IV-1patient 
(F6) with RPE65 mutation; (I) left eye of index case IV-2 (F9) with EYS mutation, (J) left eye of subject III-9 
(F10) with PDE6B mutation, (K) left eye of the proband V-1 (F7) with RPE65 mutation, (L) right eye of subject 
V-1 (F11) with deletion in FAM161A.
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achromatopsia14. Missense mutations in CNGB3 have previously been reported in two individuals with cone–
rod dystrophy and in a single individual with a progressive cone dystrophy phenotype22. Although the p.R203* 
mutation was previously associated with achromatopsia21, in family F1 it induced a more severe phenotype that 
was classified as EORD. In the past, CNGB3 was mainly screened in patients with achromatopsia in which it 
represents a common cause. With current high-throughput sequencing, most approaches analyze a large set of 
genes. This non-biased approach will most likely widen the genotype-phenotype correlation of most diseases23–25.
We also observed four families with homozygous mutations in the retinoid cycle genes. In ABCA4, a mem-
ber of the ABC transporter superfamily associated with STGD disease26, CRD, RP27,28 as well as age-related 
macular degeneration29, a p.W782* was identified in family 3 with STGD phenotype. In RPE65, a vitamin A 
trans-cis isomerase, a p.H182Y was observed in family 5. This mutation was first reported by Morimura et al. 
as a compound heterozygous mutations in a single family with two boys affected with LCA30. Interestingly, 
this amino acid has also been mutated into Asparagine and Arginine as reported in Hanein et al. and Jacobson 
et al., respectively31,32. The p.H182N and p.H182R were associated with LCA31,32. Unfortunately, there are not 
enough families with mutations at H182 to establish a strong genotype-phenotype correlation for this position. 
Mutation analysis in the region of homozygosity in family F6 revealed a new mutation c.1129-2A > G that affects 
the consensus splice site of exon 11 of RPE65 and segregates with EORD. A compound heterozygous mutation 
p.(R91W);(V172D) was discovered in one family (F7). To date, a number of different RPE65 mutations have 
been reported in patients with retinal dystrophies classified as LCA, autosomal recessive EORD or arRP30,33,34. 
However, in our cohort we found three different RPE65 mutations in three different families that correlated with 
typical RP phenotype despite the early age of onset. Morimura et al., reported a family in which a child with LCA 
phenotype is the offspring of two parents with RP23. A recent Chinese study, including 88 candidate genes in 179 
families with RD, confirmed that the average age at onset was 5 years in patients carrying mutation in RPE65 
gene24. In patients from family F4 harboring the p.R311Q, the most prevalent mutation in the nuclear receptor 
subfamily 2, group E, member 3 (NR2E3), we observed typical RP with macular atrophy, as already reported35. 
Nevertheless, Gerber et al. have shown that the p.R311Q mutation could cause late-onset arRP in Crypto-Jewish 
population36. NR2E3 recessive mutations are usually associated with enhanced S-cone syndrome, an autosomal 
recessive retinopathy in which patients have increased sensitivity to the perception of blue light while the domi-
nant p.G56R mutation is associated with severe RP21,22. A homozygous splice alteration in EYS (c.5928-2A > G) 
was reported in family F823. EYS is likely to play a role in the modeling of retinal architecture37. In previous stud-
ies, various mutations including point mutations, splice-site mutations and gross rearrangements were identified 
in patients with arRP23,38–40 and cone rod dystrophies41. The phenotype observed in family F8 resembles the RP 
phenotype reported by Barragan et al.38 in the Spanish population. The advanced age of onset of the disease could 
be correlated with our molecular result, as Huang et al. found a relationship between the advanced average age 
Figure 2. Spectrum of fundus findings among different families (F12, F13, F14, F15) with mutation in CERKL. 
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at onset and EYS mutation24. The mutation in EYS appears to be a frequent cause of arRP (15.9%) in the Spanish 
population28. Unfortunately, the prevalence of EYS mutations remains to be established in Tunisian population. 
Our preliminary analysis of the mutation load in the Tunisian population does not allow us to draw a similar 
conclusion. The fifteen families described here represent a selection that underwent whole-exome sequencing and 
thus do not represent a correct estimation of the yield of this approach.
In addition, a previously described variant (c.1354dupT) in PROM1, which encodes a pentaspan transmem-
brane glycoprotein that maintains the structural integrity of retina, was observed in patient III:1 from family F7 
affected with RP42. Mutations in PROM1 are usually associated with RP or CRD, which is the case in this family43.
We also report the identification of a new small deletion in exon 3 of FAM161A, a ciliary gene previously asso-
ciated with RP44. This mutation causes a shift in the reading frame resulting in a premature termination codon 
at position p.K227Nfs*17, presumably inhibiting protein production due to the action of the nonsense mediated 
mRNA decay. Most currently known mutations44,45 cluster in exon3 of FAM161A, which is by far the largest cod-
ing exon of this gene. FAM161A is member of the growing list of ciliary proteins implicated in human diseases. 
Figure 3. Chromatograms of the six novel mutations in CNGB1, RPE65, PDE6B, FAM161A and 
CERKL. For each mutation, wild-type (wt) sequence is depicted with the homozygous and heterozygous 
sequences. (A) c.2293C > T; p.R765C (CNGB1), (B) c.1129-2A > G (RPE65), (C) c.[325C > T];[569T > A] 
(RPE65), (D) c.1010A > G; p.H337R (PDE6B), (E) c.678_681delGAAG (FAM161A), and (F) 
c.1133 + 3_1133 + 6delAAGT(CERKL). Arrows indicate the position of the mutated nucleotide.
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Phenotypes of ciliopathies are quite diverse and may involve impairment of multiple organs or functions such as 
kidney, brain, bones, obesity and vision46. However, in the patients investigated in this study we did not observe 
any other obvious features or anamnestic history of extraocular symptoms typically related to ciliopathies. The 
phenotype was typical of RP.
Finally, it is of note that the analysis of four families (F13, F14, F15 and F16) originating from the same 
Tunisian region revealed a new homozygous deletion c.1133 + 3_1133 + 6delAAGT in the Ceramide kinase Like 
(CERKL) gene in association with RP without pigmentation. Mutations in CERKL have been described in RP 
(RP26) together with significant macular involvement during the early stages of the disease47 and cone-rod dys-
trophy which progresses to an RP-like phenotype in advanced stage48. However, the exact function of CERKL 
Family ID Disease
Genotyping 
Method
Size of 
homozygous 
region, in Mb Chromosome Gene DNA mutation
Predicted 
protein variant Coverage
Reference 
sequence
Previously 
reported SIFT Polyphen
F1 Eord WES 30.4 8q21.3 CNGB3 c.[607C > T];[607C > T] p.(R203*); (R203*) 26 NM_019098.4 [21] — —
F2 RP IROme — 16q21 CNGB1 c.[2293C > T];[2293C > T] p.(R765C); (R765C) — NM_001297.4
This study 
and [8] 0 1,00
F3 Stargardt WES 5.8 1p22.1 ABCA4 c.[2345G > A];[2345G > A] p.(W782*); (W782*) 5 NM_000350.2 [28] — —
F4 RP WES 12.2 15q23 NR2E3 c.[932G > A];[932G > A] p.(R311Q); (R311Q) 24 NM_014249.3 [35] 0.10 0.627
F5 RP WES 54.1 1p31.3-p31.2 RPE65 c.[544C > T];[544C > T] p.(H182Y); (H182Y) 36 NM_000329.2 [30] 0 0.872
F6 Eord WES 18.2 1p31.3-p31.2 RPE65 c.[1129-2A > G]; [1129-2A > G] — 30 NM_000329.2 This study — —
F7 RP IROme — 1p31.3-p31.2 RPE65 c.[325C > T];[569T > A] p.(R91W); (V172D) — NM_000329.2 This study 0.01/0.01 0.997/0.721
F8 RP WES 9 4p15.32 PROM1 c.[1354dupT];[1354dupT] p.(Y452fs*12); (Y452fs*12) 12 NM_001145848.1 [42] — —
F9 LCA WES 58 6q12 EYS c.[5928-2A > G]; [5928-2A > G] — 24 NM_001292009.1 [23] — —
F10 RP IROme — 4p16.3 PDE6B c.[1010A > G];[1010A > G] p.(H337R); (H337R) — NM_001145291.1
This study 
and [8] 1.00 0.046
F11 RP WES 13 2p15 FAM161A c.[678_681delGAAG]; [678_681delGAAG]
p.(K227Nfs*17); 
(K227Nfs*17) 94 NM_001201543 This study — —
F12 RP WES 8 2q31.3 CERKL c.[1133 + 3-1133 + 6delAAGT]; [1133 + 3-1133 + 6delAAGT] — 21 NM_201548.4 This study — —
F13 RP — — 2q31.3 CERKL c.[1133 + 3-1133 + 6delAAGT]; [1133 + 3-1133 + 6delAAGT] — — NM_201548.4 This study — —
F14 RP — — 2q31.3 CERKL c.[1133 + 3-1133 + 6delAAGT]; [1133 + 3-1133 + 6delAAGT] — — NM_201548.4 This study — —
F15 RP — — 2q31.3 CERKL c.[1133 + 3-1133 + 6delAAGT]; [1133 + 3-1133 + 6delAAGT] — — NM_201548.4 This study — —
Table 3.  Homozygous regions and mutations identified in this study.
Figure 4. RT-PCR products with primers in exon 8 and 9. (A) Schematic representation of normally spliced 
mRNA, (B) Aberrantly spliced mRNA. In the gel electrophoresis we can observe absence of splicing in the 
mutated patient (column M). In the WT sequence (column WT), splicing was not complete. *Non-spliced 
fragment, **spliced fragment.
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remains unknown. Genotype analysis of these four families showed a common disease-associated haplotype and 
supports the hypothesis of a common ancestor in this area.
Figure 5. Overview of the pedigree structure of the families and segregation analysis of disease causing 
variants in the RD cohort. Arrows point to the probands. Affected individuals are indicated with filled symbols 
(blue), suspected (grey), whereas unaffected relatives are indicated by open symbols. + : wild type allele; − : 
mutation. All mutations are homozygous except for family F7.Genes with new mutations are in bold.
www.nature.com/scientificreports/
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Despite intensive research and studies, it is still very difficult to screen for specific genes based on clinical 
observation and severity of disease. Molecular diagnosis of RD is a challenging task given the important genetic 
heterogeneity of this group of diseases.
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